IlluminOss Medical has named Manny Avila as its new chief executive officer. Avila has worked in medical device sales, operations and business managements for over two decades.
Avila was global vice president of sales and marketing for Omniguide most recently, and is a former vice president of commercial operations, surgical solutions Europe for Covidien. He has also held management roles at Aspect Medical, Synthes and Haemonetics.
“We are pleased to bring someone of Mr. Avila’s calibre on at such a pivotal time for IlluminOss,” says Robert Rabiner, founder and chief technical officer, IlluminOss Medical. “Through his extensive experience in the medical device industry, he has cultivated the knowledge and skillset we are looking for to drive adoption of the IlluminOss System as a minimally invasive alternative to traditional facture repair methods.”
The IlluminOss System has successfully treated complex fractures in over a thousand patients in Europe, where it is commercially available and has been in clinical use since 2010. Using a light-curable polymer, contained within an expandable balloon catheter, IlluminOss’ intramedullary patient-conforming implant achieves the repair and stabilisation of fractures. Benefits observed have included smaller incisions, shorter procedure times, and more rapid post-procedure patient mobility with reduced hospital stays and lower complication rates.
IlluminOss is currently executing on its first U.S. trial towards FDA approval. The U.S. Lightfix clinical trial applies IlluminOss’ approach to orthopedic fracture repair to the treatment of impending and pathologic fractures in the humerus due to metastatic bone disease.